T-cell Response to Phytohemagglutinin in the Interferon-γ Release Assay As a Potential Biomarker for the Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 May 4

PMID 33943031

Citations 3

Authors

Chisato Kamimaki

Nobuaki Kobayashi

Momo Hirata

Kohei Somekawa

Nobuhiko Fukuda

Sousuke Kubo

Seigo Katakura

Shuhei Teranishi

Keisuke Watanabe

Nobuyuki Horita

Yu Hara

Masaki Yamamoto

Makoto Kudo

Hongmei Piao

Takeshi Kaneko

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors are a standard treatment for advanced lung cancer, although it remains important to identify biomarkers that can accurately predict treatment response. Immune checkpoint inhibitors enhance the antitumor T-cell response, and interferon-γ plays an important role in this process. Therefore, this study evaluated whether the number of interferon-γ-releasing peripheral T cells after phytohemagglutinin stimulation in the interferon-γ release assay might act as a biomarker for the response of non-small cell lung cancer to immune checkpoint inhibitor treatment.

Methods: Data were retrospectively collected regarding 74 patients with non-small cell lung cancer who had received immune checkpoint inhibitors. Pretreatment screening tests had been performed using the T-SPOT.TB assay, which quantifies the number of interferon-γ-releasing T cells (as immunospots) in response to phytohemagglutinin and tuberculosis-specific antigen stimulation. Clinical factors and the number of spots in the T-SPOT fields were evaluated for associations with patient outcomes. The median number of spots was used to categorize patients as having high or low values, and the two groups were compared.

Results: Relative to patients with a low ratio, patients with a high ratio of phytohemagglutinin/tuberculosis-specific antigen spots (i.e. more responsive T cells) had significantly better progression-free survival after immune checkpoint inhibitor treatment. When we only considered patients with negative T-SPOT results, a high number of phytohemagglutinin-stimulated spots corresponded to significantly longer progression-free survival.

Conclusion: The T-SPOT.TB assay can be used to quantify the number of immunospots in response to antigen stimulation, which may predict the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.

Citing Articles

T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis.

Yoshifuji A, Toda M, Ryuzaki M, Oyama E, Kikuchi K, Kawai T Vaccines (Basel). 2023; 11(3).

PMID: 36992238 PMC: 10057502. DOI: 10.3390/vaccines11030653.

Intracellular inflammatory signalling cascades in human monocytic cells on challenge with phytohemagglutinin and 2,4,6-trinitrophenol.

Prajitha N, Mohanan P Mol Cell Biochem. 2021; 477(2):395-414.

PMID: 34775567 DOI: 10.1007/s11010-021-04296-x.

T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.

Kamimaki C, Kobayashi N, Hirata M, Somekawa K, Fukuda N, Kubo S Thorac Cancer. 2021; 12(11):1726-1734.

PMID: 33943031 PMC: 8169292. DOI: 10.1111/1759-7714.13978.

References

Zhou G, Xiong Y, Chen S, Xia F, Li Q, Hu J . Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials. Medicine (Baltimore). 2016; 95(35):e4611. PMC: 5008560. DOI: 10.1097/MD.0000000000004611. View

Kamimaki C, Kobayashi N, Hirata M, Somekawa K, Fukuda N, Kubo S . T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2021; 12(11):1726-1734. PMC: 8169292. DOI: 10.1111/1759-7714.13978. View

Cho H, Celis E . Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009; 69(23):9012-9. PMC: 2789207. DOI: 10.1158/0008-5472.CAN-09-2019. View

Jenkins R, Barbie D, Flaherty K . Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018; 118(1):9-16. PMC: 5765236. DOI: 10.1038/bjc.2017.434. View

Ilie M, Hofman P . Pros: Can tissue biopsy be replaced by liquid biopsy?. Transl Lung Cancer Res. 2016; 5(4):420-3. PMC: 5009092. DOI: 10.21037/tlcr.2016.08.06. View

Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y . PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020; 11(1):4835. PMC: 7518441. DOI: 10.1038/s41467-020-18570-x. View

Belliere J, Blancher A . QuantiFERON test interpretation in patients receiving immunosuppressive agents: an alert. Eur Respir J. 2017; 49(4). DOI: 10.1183/13993003.02102-2016. View

Katz J, Muller A, Prendergast G . Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008; 222:206-21. DOI: 10.1111/j.1600-065X.2008.00610.x. View

Teranishi S, Kobayashi N, Katakura S, Kamimaki C, Kubo S, Shibata Y . Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer. Thorac Cancer. 2020; 11(4):983-992. PMC: 7113052. DOI: 10.1111/1759-7714.13351. View

10.

Fujita K, Terashima T, Mio T . Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. J Thorac Oncol. 2016; 11(12):2238-2240. DOI: 10.1016/j.jtho.2016.07.006. View

11.

Zaidi M . The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res. 2018; 39(1):30-38. PMC: 6350411. DOI: 10.1089/jir.2018.0087. View

12.

van Eeden R, Rapoport B, Smit T, Anderson R . Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. Front Oncol. 2019; 9:659. PMC: 6668214. DOI: 10.3389/fonc.2019.00659. View

13.

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A . Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018; 10:1758834017749748. PMC: 5784541. DOI: 10.1177/1758834017749748. View

14.

Martini M, Testi M, Pasetto M, Picchio M, Innamorati G, Mazzocco M . IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010; 28(20):3548-57. DOI: 10.1016/j.vaccine.2010.03.007. View

15.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

16.

Teranishi S, Kobayashi N, Aoki A, Katakura S, Yamamoto M, Koizumi H . Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan. J Infect Chemother. 2019; 26(2):194-198. DOI: 10.1016/j.jiac.2019.08.006. View

17.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

18.

Tezera L, Bielecka M, Ogongo P, Walker N, Ellis M, Garay-Baquero D . Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. Elife. 2020; 9. PMC: 7058383. DOI: 10.7554/eLife.52668. View

19.

Komiya K, Ariga H, Nagai H, Teramoto S, Kurashima A, Shoji S . Impact of peripheral lymphocyte count on the sensitivity of 2 IFN-gamma release assays, QFT-G and ELISPOT, in patients with pulmonary tuberculosis. Intern Med. 2010; 49(17):1849-55. DOI: 10.2169/internalmedicine.49.3659. View

20.

Shin D, Zaretsky J, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A . Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2016; 7(2):188-201. PMC: 5296316. DOI: 10.1158/2159-8290.CD-16-1223. View